title: Significant increase of esophageal mucin secretion in patients with reflux esophagitis after healing with rabeprazole: its esophagoprotective potential.
abstract: Esophageal mucin secretion in patients with reflux esophagitis (RE) is significantly impaired. Rabeprazole augments gastric mucin secretion. We have studied, therefore, the effect of rabeprazole on esophageal mucin secretion in patients with RE. The study was conducted in 15 patients with RE treated with rabeprazole (20 mg QD) for 8 weeks. Esophageal secretions were collected during consecutive infusions of initial NaCl, HCl/Pepsin (HCl/P), and a final NaCl, using a specially designed esophageal catheter, before and after therapy. Mucin was measured using standard methodology. After rabeprazole administration esophageal mucin concentration as well as secretion increased during perfusion with initial saline (P < 0.01), HCl/P (P < 0.02), and concluding saline (P < 0.001). Stimulation of esophageal mucin secretion by rabeprazole may indicate that the mechanisms governing its secretion are similar to those implicated in gastric mucin output. Enhancement of esophageal mucin secretion by rabeprazole may translate into esophagoprotective potential in patients with reflux esophagitis.
authors.affiliation: Division of Gastroenterology and Hepatology, The Center for GI Nerve and Muscle Function, Gastroenterology Research Laboratory, Kansas University Medical Center, Kansas City, KS 66160, USA.
authors.forename: Irene
authors.initials: I
authors.lastname: Sarosiek
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Olyaee
authors.forename: Marek
authors.initials: M
authors.lastname: Majewski
authors.forename: Elena
authors.initials: E
authors.lastname: Sidorenko
authors.forename: Katherine
authors.initials: K
authors.lastname: Roeser
authors.forename: Sandra
authors.initials: S
authors.lastname: Sostarich
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Wallner
authors.forename: Jerzy
authors.initials: J
authors.lastname: Sarosiek
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy / Q000503:physiopathology*; D004947:Esophagus / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism*; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D009077:Mucins; D064750:Rabeprazole